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ABSTRACT
Epithelial Ovarian Cancer (EOC) is associated with dismal survival rates due to
the fact that patients are frequently diagnosed at an advanced stage and eventually
become resistant to traditional chemotherapeutics. Hence, there is a crucial need
for new and innovative therapies. Septin-2, a member of the septin family of GTP
binding proteins, has been characterized in EOC for the first time and represents a
potential future target. Septin-2 was found to be overexpressed in serous and clear
cell human patient tissue compared to benign disease. Stable septin-2 knockdown
clones developed in an ovarian cancer cell line exhibited a significant decrease in
proliferation rates. Comparative label-free proteomic analysis of septin-2 knockdown
cells revealed differential protein expression of pathways associated with the
TCA cycle, acetyl CoA, proteasome and spliceosome. Further validation of target
proteins indicated that septin-2 plays a predominant role in post-transcriptional and
translational modifications as well as cellular metabolism, and suggested the potential
novel role of septin-2 in promoting EOC tumorigenesis through these mechanisms.

INTRODUCTION

platinum-based chemotherapy, chemoresistant recurrences
are common [3]. Therefore, there is a strong need for
novel early detection methods and targeted therapies for
EOC patients.
Septin-2 is a member of the septin family, a
conserved family comprised of 13 GTP binding proteins
[4]. Septins, which are structurally observed as rods and
filaments, are vital to a number of cellular processes,
including cytokinesis, vesicle trafficking, and exocytosis
[5]. They are considered to be a fourth component of
the cytoskeleton due to their association with actin,

Epithelial Ovarian Cancer (EOC) is the most
lethal gynecologic malignancy [1]. In 2018, there will
be an estimated 22,240 new cases of EOC diagnosed and
14,070 deaths in the United States. While EOC accounts
for only 2.5 % of all female cancers, it is responsible for
5% of all cancer deaths due to low disease survival rates
[2]. These dire statistics are attributed to the fact that the
majority of patients are diagnosed at an advanced stage. In
addition, while patients generally respond well to frontline
www.oncotarget.com
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microtubules, and membranes [6]. Septins have been
identified as having a role in neurodegenerative disease,
since they were detected in brain tissue from patients
with Alzheimer disease [7]. In addition, they have been
reported to be involved in bacterial infections, Parkinson’s
disease, and male infertility [8].
In more recent years, emphasis has been placed
on investigating the role of septins in tumorigenesis
[9]. Due to their natural function in scaffolding and
membrane compartmentalization, it is plausible that they
could also play a role in the organization of membrane
associated proteins involved in diverse tumorigenic
signaling pathways [6]. Septin-9 is the most well studied
septin family member in relationship to cancer, and its
methylation status is utilized as a biomarker in colorectal
cancer [10]. However, there have also been numerous
studies linking septin-2 to neoplasia. Thus far, septin-2 has
been specifically implicated in Hodgkin’s lymphoma and
biliary tract, gastric, hepatocellular, renal cell carcinoma,
and breast cancer [11–17]. However, septin-2’s role in
EOC has not been previously investigated.
In this study, we begin to elucidate septin-2’s
function in EOC. As septins have been shown to have
diverse roles in tumorigenesis, this is the first step in
specifically defining septin-2’s contribution to EOC
pathogenesis. To establish the clinical relevance of
septin-2 in EOC, we first sought to compare levels of
septin-2 in various histological pathologies of EOC versus
benign disease. Furthermore, we present for the first time
a global analysis of septin-2 mediated proteomics in EOC
and describe signaling pathways most affected by septin-2
depletion. The results from this study lay the framework
for future mechanistic studies to determine the precise role
of septin-2 in EOC.

performed in EOC and benign tissue from our institution.
Integrated optical density (IOD) was calculated for each
sample, which revealed statistically significant higher
levels in serous (721 area*mean/1E+06, p = 0.04)
(Figure 1B–1C) and clear cell (31 area*mean/1E+06,
p = 0.009) histopathologies (Figure 1D–1E) compared to
respective benign controls (239 area*mean/1E+06) and (6
area*mean/1E+06). Staining results were further validated
with an independent antibody in five clear cell EOC, five
serous EOC and four benign samples (Supplementary
Figure 1A–1B).

Stable knockdown of septin-2 influences cell
proliferation
In order to study septin-2’s function in EOC, stable
septin-2 knockdown shRNA clones were generated in
human serous ovarian SKOV3 wild type (WT) cells. Two
clonal populations were employed for these studies—
knockdown 9 (KD9) and knockdown 11 (KD11)—based
on confirmation of successful septin-2 downregulation.
A stable line was also generated by clonal expansion of
cells transfected with scrambled oligo control shRNA,
designated Plasmid C. To confirm the efficacy of
knockdowns at the genomic level, qPCR was employed.
Septin-2 levels in KD9 were 1.93- and 4.16-fold lower
than WT and Plasmid C cells, respectively. Septin-2 levels
in KD11 were 1.67- and 3.88-fold lower than WT and
Plasmid C cells, respectively (Figure 2A).
To further validate successful knockdown of septin-2,
protein levels were detected by Western blot. We observed
substantial decreases in septin-2 levels in KD9 and KD11
compared to the WT and Plasmid C controls (Figure 2B).
Septin-2 levels in KD9 were 0.28-fold relative to WT and
0.38-fold reduced relative to Plasmid C. Septin-2 levels in
KD11 were 0.24-fold and 0.32-fold reduced relative to WT
and Plasmid C, respectively (Figure 2C).
To begin to determine the consequence of septin-2
knockdown in SKOV3 cells, proliferation of the shRNA
clones was evaluated. WT, Plasmid C, KD9, and KD11
cells were seeded at equal cell densities and allowed to
expand. The cells were trypsinized at 72 and 96 hours,
and numbers of live cells in each clonal population were
quantified (Figure 2D). At 72 hours, KD9 clones exhibited
a 0.33-fold reduction in cell proliferation compared to WT,
and a 0.40-fold reduction compared to Plasmid C. KD11
clones demonstrated a 0.34-fold and 0.41-fold reduction
in proliferation from respective WT and Plasmid C cell
numbers. The 96-hour time point revealed a 0.49-fold
reduction in KD9 cells compared to WT and a 0.61-fold
reduction compared to Plasmid C. KD11 cells showed
a 0.37-fold and 0.46 fold- decrease compared to WT
and Plasmid C cells, respectively. All decreases in cell
counts displayed by KD9 and KD11 at both time points
were determined to be statistically significant (p < 0.02).
Differences in viability between WT, Plasmid C, KD9,

RESULTS
Septin-2 is overexpressed in EOC
To establish the clinical relevance of septin-2 in
EOC, we evaluated its levels in EOC samples of a variety
of histologies, and compared these to levels in benign
controls. Immunohistochemical analysis of septin-2
levels in a human ovarian tissue microarray comprising
normal, serous, mucinous, clear cell, and dysgerminoma
histopathologies revealed that mean intensity of the
septin-2 staining was statistically significantly greater in
serous EOC (703.38 pixels) than in adjacent normal tissue
(539 pixels) (p = 0.0037) (Figure 1A). While all other
histopatholgies exhibited higher mean intensity levels of
septin-2—mucinous (603 pixels), clear cell (821 pixels),
and dysgerminoma (744 pixels)—compared to the normal
adjacent tissue, none were considered statistically significant,
possibly due to low numbers of samples available.
To further investigate expression levels of septin-2
in patient samples, immunohistochemistry of septin-2 was
www.oncotarget.com
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Proteomic analysis of septin-2 knockdown in
EOC cells

and KD11 determined by live/dead counts were found to
be non-significant (Supplementary Figure 2), confirming
that our findings were not due to increased cell death.
This finding strongly suggests that the downregulation
of septin-2 has a profound impact on cell proliferation in
EOC cells.

A comparative label-free proteomic analysis was
performed to examine global protein expression level
differences resulting from the knockdown of septin-2.

Figure 1: Septin-2 is overexpressed in EOC. (A) A commercially available human ovarian tissue microarray was stained with

Septin-2 primary antibody and examined by confocal microscopy. Staining in all histopathogies was then quantified via mean intensity.
(B) Paraffin-embedded human EOC tissue slides were stained for Septin-2 and expression was analyzed by integrated optical density. (C)
Representative images of Serous EOC staining (left panel) vs benign (right panel). (D) Staining of paraffin-embedded human clear cell
EOC tissue and benign controls with septin-2 was performed and expression was assessed by IOD. (E) Representative images of clear cell
EOC staining (left panel) vs benign (right panel).
www.oncotarget.com
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Interestingly, significant differences in protein-peptide
levels between control cells and septin-2 knockdowns
was observed only in KD11 populations, even though our
proliferation results demonstrated that KD9’s phenotype
was similar to that of KD (Supplementary Dataset). In
order to test the hypothesis that spontaneous loss of the
knockdown had occurred in KD9 cells during cell culture,
we reexamined septin-2 levels in each of the clonal cell
lines and verified that septin-2 knockdown was indeed lost
in KD9 cells, while the KD11 cells had retained septin-2
knockdown (Supplementary Figure 3). Therefore, we
proceeded with analysis using KD11 cells. As expected, a
principal component analysis of three biological replicates
of WT, Plasmid C, and KD11 revealed separate clusters

when comparing principal component 1 (PC1) and PC2
scores (Figure 3). In contrast, for KD9 sample, the 3
biological replicates were very scattered (data not shown).
Therefore, any further analysis or validation of KD9 was
not included.
Mass spectrometry of the control and knockdown
cells identified 19976 unique peptides corresponding to
3565 unique proteins. Of those, only one peptide/protein in
Plasmid C exhibited an absolute fold change greater than 1
with a q-value < 0.05 compared to WT (Figure 4A). This
result allowed us to conclude that there was no significant
difference between both control cell populations. Conversely,
5% of all peptides in KD11 cells revealed relative fold
change greater than 1 (q < 0.05) compared to WT cells. In

Figure 2: Stable septin-2 knockdown shows a decrease in proliferation. (A) Gene expression levels of septin-2 in KD9 and

KD11 compared to WT and Plasmid C control levels determined by quantitative PCR (qPCR). (B) Verification of septin-2 knockdown
at protein level visualized by Western blot. A single blot was probed simultaneously for septin-2 and GAPDH as a loading control. The
original blot can be seen in Supplementary Figure 4. (C) Relative band density of (B) normalized to GAPDH. (D) Proliferation rates of KD9
and KD11 compared to control WT and Plasmid C were assessed at 72 and 96 hours by total live cell counts.
www.oncotarget.com
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q = 0.30) (Figure 4C). It is interesting to note that, all four
of these proteins have previously been shown to play a role
in tumorigenesis [18–21]. Heat maps were constructed to
illustrate the clustering of the 231 differentially expressed
proteins in each of the three replicates of WT, Plasmid C, and
KD11 (Figure 5A) and representative peptides in the most
differentially expressed proteins (Figure 5B). Comparison of
both heat maps reveals an overall similar pattern of peak-area
quantitation, with many of the proteins and peptide sequences
within KD11 exhibiting downregulation compared to WT
and Plasmid C controls.

addition, 93.5% of those peptides identified as exhibiting
substantial expression differences displayed a lower peak
area in KD11 compared to WT, indicating a majority of
peptides were downregulated (Figure 4B). Representative
examples of peak-area of four peptide sequences from the
proteins galetin-3 binding protein (LFALS3BP), transketolase
(TKT), poly(A) binding protein (PABPC4), and enolase1(ENO1) show differential expression between control
and knockdown cells. KD11/WT peak area ratios were
calculated for LFALS3BP (0.051, q = 0.012), TKT (0.081,
q = 0.0012), PABPC4 (0.50, q = 0.011), and ENO1 (632.7,

Figure 3: Principal component analysis of WT, Plasmid C, and KD11 samples. WT, Plasmid C and KD11 show clustering in

visualization of principal component 1(PC1) versus principal component 2 (PC2) (A) wherein WT is more dispersed and shows overlap
with Plasmid C in PC1 vs PC3 (B).

Figure 4: Volcano plot of fold change versus q-value of peak area for distinct peptides. Of the 19976 distinct peptides (3565
proteins) identified, (A) only one peptide/protein (0%, red in inset pie chart) in Plasmid C and (B) 5.0% peptides in KD11 showed large
difference (absolute fold change more than 1, and q < 0.05) against WT. Nearly 93.5% peptides showed lower peak-area (down regulation)
in KD11. (C) Examples of peak-area/expression levels in replicates for four peptides are shown: 1. Galectin-3-binding protein (LGALS3BP,
UniProtID: K7EKQ5), 2. Transketolase (TKT, P29401), 3. Poly(A) binding protein 4 (PABPC4, Q4VC03), 4. Enolase 1 (ENO1, P06733).
The peptide sequence, KD11/WT peak-area ratio, and respective q-values are listed for each protein.
www.oncotarget.com
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Figure 5: Hierarchical clustering and heat map of differentially expressed proteins and peptides. (A) Clustering of the

231 differentially expressed proteins. (B) Peptides in most differentially expressed proteins, for example, in ribosome binding protein
1(Q9P2E9 (RRBP1, Ribosome binding protein 1 UniProtID: Q9P2E9) with 60 peptides, showing an overall similar pattern of peak-area
quantitation. Peptides/proteins show mostly down regulation in KD11 samples, which form a distinct cluster.
www.oncotarget.com
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Finally, gene ontology (GO) analysis with
differentially expressed proteins showed enrichment of
proteasomal/ubiquitin in the biological process category
and RNA binding in the molecular function category
(Figure 6). Enrichment was also noted for terms related to
the ribonucleoprotein complex and cytosol in the cellular
component category. KEGG pathway analysis revealed
citric acid cycle (TCA cycle) and spliceosome enrichment
among differentially expressed proteins (Figure 6).
Representative proteins related to these pathways
were further validated by immunoblot analysis in
triplicate. Enolase, LDHA, Transketolase, and FASN
expression in WT and KD11 was examined via Western

blot (Figure 7A). Band density normalized to GAPDH
revealed a 1.2-fold increase in Enolase expression from
WT to KD11, although this change was not significant
due to one replicate showing no increase. LDHA,
Transketolase, and FASN levels in KD11 were 0.70-fold
(p = 5.5 × 10–4), 0.43-fold (p = 0.001), and 0.35-fold (p
= 2.5 × 10–5) lower relative to WT control. (Figure 7B).

DISCUSSION
For the first time, we have characterized septin-2
function in EOC and examined its proteomic effects on
a global level. Several biological pathways were found

Figure 6: Gene ontology (GO) analysis using DAVID (https://david.ncifcrf.gov/). Proteins with differential expression (n = 231,

q < 0.05, in KD11 versus WT is compared with proteins (n = 3334) that showed no differential expression. The former showed enrichment
for proteasomal/ubiquitin related GO terms (q << 0.05, Bonferroni) in the biological process (BP) category. In cellular component (CC) and
molecular function (MF) categories, differentially expressed proteins showed enrichment for ribonucleoprotein and RNA related terms. No
enrichment was seen in the molecular function category. Differentially expressed proteins showed enrichment for KEGG pathways relating
to citrate cycle/energy and spliceosome.

Figure 7: Verification of enriched proteins identified by proteomic analysis. (A) Triplicate Western blot analysis of protein
expression validated in both WT and KD11. Blots were probed for GAPDH, then subsequently stripped and re-probed for each individual
validated protein. Original blots from all three replicates can be seen in Supplementary Figure 4. (B) Relative Band Densities of proteins in
(a), normalized to GAPDH. *p < 0.05 **p < 0.005, ***p < 0.0005.
www.oncotarget.com
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to be differentially regulated in septin-2 knockdown
ovarian cancer cells, exemplified by representative
proteins from Figure 4C. Galectin-3 is a member of the
β-galactoside binding protein family that is involved in
diverse functions inherent to cancer, such as metastasis,
immune surveillance, inflammation, apoptosis, molecular
trafficking, and mRNA splicing [22]. Transketolase is a
pentose phosphate pathway enzyme essential for cancer
growth due to its ability to control NADPH production and
counteract oxidative stress [20]. Poly(A) binding protein
is a highly conserved protein that plays an important
role in mRNA stabilization and translation [23], which
controls cell growth, proliferation, and differentiation [24].
Enolase1, found to be differentially expressed in cancer, is
a key glycolytic enzyme that catalyzes 2-phosphogylgerate
to phosphoenolpyruvate in the last steps of the glycolytic
catabolic pathway [25].
Of these pathways identified, it was most expected
that autophosphorylation and proteasomal/ubiquitin
protein functions were affected by septin-2 knockdown.
It has been previously established that proper control
of septins’ phosphorylation status is required for the
completion of cytokinesis [26]. In fungus, Meseroll et al
(2013) discovered that changes in specific phosphorylation
sites on septins (Cdc3p and Cdc11p) leads to the
disruption of higher order septin structures, indicating
septin phosphorylation is also a vital regulator of their own
structure formation [27].
Similar to phosphorylation, ubiquitination
represents another important septin post-translational
modification. Septins have an established role interacting
with proteins involved in degradation pathways, such as
ubiquitin ligases and de-ubiquitylating enzymes, which
modulates protein turnover [12, 28, 29]. Recently, it has
also been reported that SUMOylation of human septins
is a critical process contributing to proper septin filament
bundling and cytokinesis [30]. Unlike ubiquitin, SUMO
(small ubiquitin-like modifiers) modification does not
always lead to protein degradation, as SUMOylation can
also modulate localization, interaction, and activity of the
target protein [31]. Ribet et.al (2017) reported that septin-7
is constitutively SUMOylated throughout the cell cycle,
and septin variants that are unable to be SUMOylated halt
septin bundle formation and lead to defects in cytokinesis,
highlighting its crucial role in septin filament bundling and
cell division [30].
GO analysis revealed that septin-2 is also involved
in post-transcriptional modifications, as the spliceosome
pathway was found to be enriched among septin-2
regulated proteins (Figure 6). This result suggests
that septin-2 plays a major role in the editing of both
precursor messenger RNA (pre-mRNA) and proteins.
The spliceosome, a large molecular complex involved
in the removal of non-coding introns from pre-mRNA,
represents a potential oncogenic target as evidence has
shown that tumors rely on normal spliceosome function for
www.oncotarget.com

cell survival [32, 33]. In addition, Poly(A) binding protein,
which we reported as an example of a differentially
expressed protein (Figure 4C), is a translation initiation
factor that binds to the mRNA 3’poly(A) tail [24] and
influences cell growth and survival. Since we have
shown that the knockdown of septin-2 promotes irregular
expression of a multitude of pathways related to mRNA
and protein modifications, it seems reasonable that its
downregulation would also affect tumor cell growth.
As the depletion of septins can lead to cytokinesis
failure, it is logical that cellular proliferation would
subsequently be affected [30]. In this study, we observed a
reduction in proliferation with septin-2 knockdown (Figure
2D). Corroborating results from our study in EOC, Zhang
et al (2016) treated breast cancer cells with the broad
septin inhibitor forchlorfenuron (FCF) and also observed
a decrease in cell proliferation [17], which they attributed
to the suppression of MEK and ERK1/2 (extracellular
signal-regulated kinase 1/2) signaling [17]. Another study
showed that septin-8 interacts with MAPK5 (mitogen
activated protein kinase 5), further suggesting that septins
play a role in the MAPK/ERK pathway [34]. Septin-9 has
also been implicated in cell proliferation, as a septin-9
variant SEPT9_i1 binds to c-Jun-N terminal kinase (JNK),
preventing its degradation and therefore promoting tumor
cell proliferation [4]. In addition, another septin-9 variant
SEPT9_i3 has been found to be phosphorylated by cellcycle-dependent kinase 1 (CDK1), controlling entry into
mitosis and promoting cell survival and proliferation [35].
These investigations highlight that septin-2, and septins in
general, play an important role in cellular proliferation and
potentially promote tumor growth.
Interestingly, the most novel conclusion drawn
from this investigation was the robust enrichment seen
in cellular metabolism and energy dynamics in proteins
affected by septin-2 downregulation. This novel finding
regarding septin-2 is in agreement with previous
studies reporting on septin functions related to energy
metabolism. One study found that in Shigella bacteria,
host cell glycolysis becomes dysfunctional when septin-2
and septin-7 are depleted, indicating that septins may play
a role in the modulation of glycolysis [36]. An additional
study identified that fungal septins FaCdc3 and FaCdc12
are required for lipid metabolism [37]. Moreover,
septin-9 was found to induce lipid droplet growth through
binding to phosphatidylinositol-5-phosphate (PtdIns5P),
a phospholipid with a well-established role in dynamics
and intracellular membrane trafficking [38]. PtdIns5P
binding in turn controls septin-9 filament formation
and its interaction with microtubules [39]. Furthermore,
septin-11 was found to be expressed in human adipocytes
and upregulated in obese individuals. SEPT11 mRNA was
positively correlated with markers of insulin resistance in
adipose tissue, and silencing of septin-11 muted insulin
signaling and insulin-induced lipid accumulation in
adipocytes [40].
2966
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Our findings, however, represent the first time a septin
family member has been implicated in cellular metabolism
as it relates to tumorigenesis. Acetyl-CoA, one of the
pathways most differentially expressed by septin-2, is a key
metabolic player that links glycolysis, fatty acid oxidation,
ketogenesis, amino acid metabolism, the TCA cycle, and
lipid synthesis [41]. In normoxic conditions, acetyl-CoA is
derived from glucose. However, under hypoxic conditions
like in cancer, acetyl-CoA has been to found to derive from
acetate, suggesting that targeting the acetyl-CoA pathway
in cancer could represent a viable treatment option [42].
The TCA cycle, another important metabolic pathway, was
also deregulated in the septin-2 knockdown clones. While
previous dogma stated that tumor cells do not utilize the TCA
cycle for energy, it has now been found that some cancer
cells with deregulated oncogenes and tumor suppressor
genes actually do rely on the TCA cycle [43]. In addition,
the metabolic proteins transketolase and enolase, which are
involved in glycolysis and the pentose phosphate pathway,
respectively, were found to be differentially expressed by
septin-2 inhibition (Figure 4C), demonstrating that septin-2 is
involved in various facets of cellular metabolism within EOC.
Pathways related to metabolism and energy production have
previously been found to contribute to EOC tumorigenesis,
as it has been shown that glycolysis drives chemoresistance
in EOC and that high levels of fatty acid synthase (FASN)
contribute to tumor cell growth through the promotion of
human epidermal growth factor [44, 45]. Therefore, it can be
hypothesized that the inhibition of septin-2 would exhibit a
therapeutic effect in EOC via suppression of tumor metabolic
pathways.
Overall, our study demonstrates the novel finding
that septin-2 is involved in EOC pathogenesis. This
investigation represents a springboard for future studies to
determine the efficacy of septin-2 inhibition, in addition to
more clearly elucidating its diverse mechanistic pathways
in EOC tumorigenesis. While our proteomics study was
performed in a serous ovarian cancer cell line, it would
be interesting to repeat the stable knockdown experiment
in a clear cell EOC line, since septin-2 was also found
to be overexpressed in this histopathology. Additionally,
both in vitro and in vivo studies could be performed to
confirm that inhibition of septin-2 affects cell viability and
tumor growth in order to determine if targeting of septin-2
synergizes with platinum-based chemotherapeutics.

shRNA for human septin-2 (Santa Cruz
Biotechnology, sc-40936-SH) or scrambled oligonucleotide
control shRNA (Plasmid-C; Santa Cruz Biotechnology,
sc-108066) was transfected into SKOV3WT cells using
Lipofectomine® 2000 (Invitrogen, 11668) following the
manufacturer’s instructions. Individual single cells were
selected by culturing under the pressure of 5 ug/mL of
puromycin (Research products International, 58-58-2), and
clonal populations were allowed to expand. Phenotypes of
the clones were evaluated by Western blotting using anti
Septin-2 antibody (Novus Biologicals, NBP1-85212).

Proliferation assay
SKOV3WT, Plasmid C, and knockdown lines
(KD9 and KD11) were plated at equal densities in
100 × 20 mm plates. Cells were trypsinized at 72 and
96 hours, and replicates of three were counted using a
hemocytometer with trypan blue staining to compare
proliferation rates. The experiment was repeated three
times and error bars represent standard deviation.
Statistical significance was determined by an unpaired,
two-tailed Student t-test, where p < 0.05 was considered
significant. To ensure all cells had comparable viabilities,
WT, Plasmid C, KD9, and KD11 were plated at equal
densities in 60 × 20 mm plates. Cells were trypsinized at
72 hours and replicates of three were assessed via trypan
blue staining and live/dead counts using a Nexcelom
Biosciences Auto T4 Cellometer.

Immunohistochemistry and confocal
immunofluorescent microscopy
Formalin-fixed paraffin embedded human
ovarian tissue slides were obtained from the Women
and Infants Pathology Department. The human ovarian
tissue microarray was obtained from US Tissue Biomax
(OV802a). Slides obtained from Women and Infants were
baked at 65°C for two hours, and the microarray for 20
minutes. All slides were subsequently washed in xylene,
100% ethanol, 95% ethanol, 70% ethanol, deoxygenated
water, and FTA Hemagglutination Buffer. Antigen retrieval
was then performed using DAKO antigen retrieval
solution (10x) (Agilent, S1699), heated to 95°C for 20
minutes. Slides were then blocked with 5% horse serum
in FTA Hemagglutination Buffer and incubated overnight
in primary Septin-2 antibody (Santa Cruz, sc-20408) at
4°C. Secondary antibody, Alexa Fluora 488-conjugated
donkey anti-Goat IgG (H+L) (Thermo Fisher Scientific,
A-11055) was then added to slides following incubation
in the dark for one hour at room temperature. Slides were
washed in between steps with FTA Hemagglutination
Buffer and were cover-slipped with DAPI containing
mounting medium (Vector Laboratories, H-1200). While

MATERIALS AND METHODS
Cell culture
SKOV3 wild type (SKOV3WT) cells were obtained
from American Type Culture Collection (ATCC) and were
cultured at low passage in Dulbecco’s Modified Eagle
Medium supplemented with 10% fetal bovine serum and
1% penicillin/streptomycin in a humidified incubator at
37°C/5% CO2.
www.oncotarget.com
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this primary Septin-2 antibody has been discontinued,
results were replicated in a separate staining experiment
in which the overexpression of septin-2 in serous and
clear cell histopathogies compared to benign controls
was confirmed with a commercially available antibody
(Thermo Fisher Scientific PA5-27517). This antibody
was also used to perform confirmatory staining of WT
and KD11 cells. Secondary antibody Dylight 488 antirabbit IgG (Vector Laboratories, DI-1488) was then used
(Supplementary Figure 1).
Images were acquired using a Nikon E800
microscope (Nikon Inc. Mellville, NY, USA) and an RT3
SPOT camera (Diagnostic Instruments, Sterling Heights,
MI, USA). Random sampling of ten fields was based on
DAPI staining. Mean intensity (used as a measurement
for the tissue microarray as all areas for tissue were
uniform) or integrated optical density (IOD) expressed as
area*mean/1E+07, was acquired using a 40X objective.
IOD was reported with staining performed with tissue
obtained from our institution, as the size of each sample
was variable. Statistical significance was determined by
an unpaired, two-tailed Student t-test, where p < 0.05 was
considered significant.

Enolase (Santa Cruz Biotechnology, sc-100812 [1:500])
Transketolase (Santa Cruz Biotechnology, sc-390179)
[1:500]).

Quantitative PCR
RNA was extracted from cells by Trizol /LiCl
precipitation. Total RNA (1000 ng) was then reverse
transcribed into cDNA using the iScript cDNA Synthesis
Kit (Bio-Rad, 1708890), following the manufacturer’s
protocol. Quantitative PCR was performed in triplicate
by loading 1 μl cDNA reaction, 1 μM forward and reverse
validated Septin-2 primers (Origene HP232247), 10 μl
SYBR Green (Applied Biosciences [ABI], 4367659)
and 5 μl RNAse-free water to each well. Samples were
run using the ABI 7500 Fast Real-Time PCR System.
Data was then analyzed using the ΔΔCt method. All gene
expression levels were normalized to 18s rRNA.

Densitometry
Densitometry analysis of Western blots was
performed using image J. Blot images were analyzed
in 8-bit JPEG format, using the “analyze gel” function.
Relative band densities were normalized to GAPDH
loading control.

Western blot
Protein was extracted from cell pellets in Cell
Lysis Buffer (Cell Signaling, 9803) with 1 mM of
PMSF, according to the manufacturer’s protocol. The
concentration of extracted proteins was determined by DC
Protein Assay (Bio-Rad Laboratories, 5000116). Western
blot analysis was performed by loading equal amounts
of protein boiled at 70°C with Novex Sample Reducing
Agent (Life Technologies, NP009) and NuPAGE LDS
sample buffer (ThermoFisher Scientific, NP0007) into
a 4–12% gradient NuPAGE Novex Bis-Tris gel (Life
Technologies, NP0321BOX). The gel was then transferred
using a semi-dry transfer to methanol-activated 0.2 μm
PVDF membranes (Bio-Rad, 162-0177) at 0.12-0.24A
for 80 minutes. Membranes were blocked in 5% milk in
phosphate-buffered saline with 0.05% Tween 20 (PBS-T)
for 30 minutes at room temperature. Finally, membranes
were incubated in primary antibody diluted in 5%
milk in PBS-T overnight at 4°C, and then in secondary
antibody diluted in 5% milk in PBS-T for 1 hour at room
temperature, with PBS-T washes in between. Amersham
ECL Prime Western Blot Detection System (GE
Healthcare, RPN2232) was employed for detection of the
HRP-tagged secondary antibodies. The Biorad Chemidoc
MP Imaging System was used to image all blots. GAPDH
was used as a loading control. Antibodies and respective
dilutions used are as follows:
GAPDH (Cell Signaling, 2118, [1:2000])
Septin-2 (Novus Biologicals, NBP1-85212, [1:500])
LDHA (Cell Signaling, 3582S, [1:1000])
FASN (Cell Signaling, 3180S, [1:1000])
www.oncotarget.com

Sample preparation for LC-MS/MS analysis
Cell pellets were suspended in lysis buffer (8 M urea,
1 mM sodium orthovanadate, 20 mM HEPES, 2.5 mM
sodium pyrophosphate, 1 mM β-glycerophosphate, pH
8.0, 20 min, 4°C), sonicated and cleared by centrifugation
(14 000 × g, 15 min, 4°C). Protein concentration was
measured (Pierce BCA Protein Assay, Thermo Fisher
Scientific, IL, USA) and a total of 100 µg of protein per
sample was digested with trypsin. Tryptic peptides were
desalted using C18 Sep-Pak plus cartridges (Waters,
Milford, MA, USA) and were lyophilized for 48 hours to
dryness. The dried eluted peptides were reconstituted in
buffer A (0.1 M acetic acid) at a concentration of 1 µg/µl,
and 5 µl was injected for each analysis.
The LC-MS/MS was performed on a fully
automated proteomic technology platform [46, 47] that
includes an Agilent 1200 Series Quaternary HPLC system
(Agilent Technologies, Santa Clara, CA, USA) connected
to a Q Exactive Plus mass spectrometer (Thermo Fisher
Scientific, Waltham, MA, USA). The LC-MS/MS set
up was used as described previously [48]. Briefly, the
peptides were separated through a linear reversed-phase
90 minutes gradient from 0% to 40% buffer B (0.1 M
acetic acid in acetonitrile) at a flow rate of 3 µl /min
through a 3 µm 20 cm C18 column. The electrospray
voltage of 2.0 kV was applied in a split flow configuration,
and spectra were collected using a top-9 data-dependent
method. Survey full scan MS spectra (m/z 400-1800)
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were acquired at a resolution of 70,000 with an AGC
target value of 3 × 106 ions or a maximum ion injection
time of 200 ms. The peptide fragmentation was performed
via higher-energy collision dissociation with the energy
set at 28 NCE. The MS/MS spectra were acquired at a
resolution of 17,500, with a targeted value of 2 × 104
ions or a maximum integration time of 200 ms. The ion
selection abundance threshold was set at 8.0 × 102 with
charge state exclusion of unassigned and z = 1, or 6–8 ions
and dynamic exclusion time of 30 seconds.

of 80 seconds, signal to noise threshold of 10 and detection
of peak limits via descent on the non-transformed data
enabled. SIC peak areas were determined for every peptide
that was identified by MS/MS. In the case of a missing MS/
MS for a particular peptide, in a particular replicate, the SIC
peak area was calculated according to the peptide’s isolated
mass and the retention time calculated from retention time
alignment. A minimum SIC peak area equivalent to the
typical spectral noise level of 1000 was required of all data
reported for label-free quantitation. Individual SIC peak
areas were normalized to the peak area of the standard
synthetic peptide DRVYHPF that was exogenously spiked
prior to reversed-phase elution into the mass spectrometer.
Quantitative analysis was applied to replicate experiments.

Database search
Peptide spectrum matching of MS/MS spectra of
each file was searched against a species-specific database
(UniProt; downloaded 2/1/2015) using MASCOT v. 2.4
(Matrix Science, Ltd, London, UK). A concatenated
database containing “target” and “decoy” sequences was
employed to estimate the false discovery rate (FDR)
[49]. Msconvert from ProteoWizard (v. 3.0.5047), using
default parameters and with the MS2Deisotope filter
on, was employed to create peak lists for Mascot. The
Mascot database search was performed with the following
parameters: trypsin enzyme cleavage specificity, 2 possible
missed cleavages, 10 ppm mass tolerance for precursor
ions, 20 mmu mass tolerance for fragment ions. Search
parameters permitted variable modification of methionine
oxidation (+15.9949 Da) and static modification of
carbamidomethylation (+57.0215 Da) on cysteine. The
resulting peptide spectrum matches (PSMs) were reduced
to sets of unique PSMs by eliminating lower scoring
duplicates. To provide high confidence, the Mascot results
were filtered for Mowse Score (>20). Peptide assignments
from the database search were filtered down to a 1%
FDR by a logistic spectral score as previously described
[49, 50]. The mass spectrometry proteomics data have
been deposited to the ProteomeXchange Consortium via
the PRIDE partner repository with the dataset identifier
PXD010166. Raw data is also available within the
Supplementary Dataset file of this manuscript.

Bioinformatics analyses
To select peptides that showed a statistically
significant change in abundance between control vs
treatment cells, q-values for multiple hypothesis tests
were calculated based on p-values from two-tailed
unpaired Student’s t tests using the R package QVALUE
as previously described [52, 53]. Peptide peak-areas are
summed to get protein-level quantification where required
[54]. All calculations were done in R programming
language and volcano plot/graphs were plotted in Excel.
Principal component analysis (PCA) and
hierarchical clustering/heat map were also performed in
R. Gene ontology (GO) analysis was performed using
Enrichr (http://amp.pharm.mssm.edu/Enrichr/) for
differentially expressed peptides/proteins [54] in KD11
versus WT against the background of unchanged proteins.

Abbreviations
EOC: epithelial ovarian cancer; GO: gene ontology;
IOD: integrated optical density; KD: knockdown;
PCA: principal component analysis; SIC: selected ion
chromatograms.
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parameters: mass window of 10 ppm, minimum peak
widths ranging from 2 to 20 seconds, maximum peak width
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